Author:
Yamazaki Daiju,Kitaguchi Takashi,Ishimura Masakazu,Taniguchi Tomohiko,Yamanishi Atsuhiro,Saji Daisuke,Takahashi Etsushi,Oguchi Masao,Moriyama Yuta,Maeda Sanae,Miyamoto Kaori,Morimura Kaoru,Ohnaka Hiroki,Tashibu Hiroyuki,Sekino Yuko,Miyamoto Norimasa,Kanda Yasunari
Funder
Mochida Pharmaceutical Co. Ltd.
Kaken Pharmaceutical Co. Ltd.
Eisai Co. Ltd.
Kyorin Pharmaceutical Co. Ltd.
NISSEI BILIS Co. Ltd.
Toyama Chemical Co. Ltd.
Ina Research Inc.
Veritas Co. Ltd.
Research on Regulatory Science of Pharmaceuticals and Medical Devices of the Japan Agency for Medical Research and Development
Subject
Pharmacology,Molecular Medicine
Reference25 articles.
1. The Non-Clinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals;ICH S7B,2005
2. Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium;Sager;Am Heart J,2014
3. The comprehensive in vitro proarrhythmia assay (CiPA) initiative - update on progress;Colatsky;J Pharmacol Toxicol Meth,2016
4. Points to consider for a validation study of iPS cell-derived cardiomyocytes using a multi-electrode array system;Kanda;J Pharmacol Toxicol Meth,2016
5. Electrophysiological characteristics of human iPSC-derived cardiomyocytes for the assessment of drug-induced proarrhythmic potential;Yamamoto;PLoS One,2016
Cited by
31 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献